OFF LABEL USE is the #10 most commonly reported adverse reaction for ABATACEPT, manufactured by E.R. Squibb & Sons, L.L.C.. There are 11,743 FDA adverse event reports linking ABATACEPT to OFF LABEL USE. This represents approximately 1.8% of all 665,237 adverse event reports for this drug.
Patients taking ABATACEPT who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
OFF LABEL USE11,743 of 665,237 reports
OFF LABEL USE is a less commonly reported adverse event for ABATACEPT, but still significant enough to appear in the safety profile.
Other Side Effects of ABATACEPT
In addition to off label use, the following adverse reactions have been reported for ABATACEPT:
OFF LABEL USE has been reported as an adverse event in 11,743 FDA reports for ABATACEPT. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is OFF LABEL USE with ABATACEPT?
OFF LABEL USE accounts for approximately 1.8% of all adverse event reports for ABATACEPT, making it a notable side effect.
What should I do if I experience OFF LABEL USE while taking ABATACEPT?
If you experience off label use while taking ABATACEPT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.